US FDA approves Ionis Pharma's genetic disorder drug

Published on 20 Dec 2024 on Reuters

, opens new tab drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on...

Read the rest of the article

Start tracking your investments with Statfolio

Ionis Pharmaceuticals EVP sells $241,628 in stock

Investing.com 17 Jan 2025

Ionis Pharmaceuticals CFO sells stock worth $290,989

Investing.com 17 Jan 2025

Brett Monia, Chief Executive Officer of Ionis Pharmaceuticals Inc. (NASDAQ:IONS), recently sold a...

Investing.com 17 Jan 2025

Brian Birchler, Executive Vice President of Corporate and Development Operations at Ionis...

Investing.com 17 Jan 2025

Bennett C. Frank, Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals...

Investing.com 17 Jan 2025

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 17 Jan 2025

(NASDAQ:IONS) by taking the expected future cash flows and discounting them to today's value. One...

Simply Wall St. · via Yahoo Finance 23 Dec 2024

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Tryngolza (olezarsen) a...

Benzinga · via Yahoo Finance 21 Dec 2024

The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the...

Zacks · via Yahoo Finance 20 Dec 2024

Valued at around $11.95 million, the firm's ARK Innovation ETF and ARK Genomic Revolution ETF...

GuruFocus.com · via Yahoo Finance 20 Dec 2024